Blog
About

1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The human monoclonal antibody denosumab inhibits osteoclast-mediated bone resorption by binding to receptor activator of nuclear factor κB ligand (RANKL), which is upregulated by tumor cells. Denosumab is indicated to prevent skeletal-related events (SREs) from osteoporosis and metastatic bone disease. We report a case of denosumab-induced hypocalcemia to highlight potential toxicity and treatment considerations. A 66-year-old man with prostate cancer, small cell lung cancer, and bone metastases presented with fatigue, weakness, and muscle spasm. Sixteen days prior, he received cycle 6 of cisplatin and etoposide, leuprolide, and denosumab (120 mg subcutaneously). His examination demonstrated a slight resting tremor, normal strength, and negative Chvostek sign. Laboratory analysis revealed hemoglobin, 8.0 g/dL; total calcium, 5.2 mg/dL (pre-denosumab, 8.9 mg/dL); and magnesium, 0.7 mg/dL. He initially received two units packed red blood cells, intravenous calcium and magnesium, and vitamin D. During his hospitalization, he required multiple doses of intravenous and oral calcium, magnesium, and vitamin D. Despite ongoing oral supplementation, his post-discharge serum calcium fluctuated significantly, requiring close monitoring and frequent dose adjustments. Denosumab's unique antiresorptive properties yield fewer SREs. The trade-off is increased hypocalcemia risk, which may be severe and require aggressive, prolonged supplementation and monitoring.

          Related collections

          Author and article information

          Journal
          J Med Toxicol
          Journal of medical toxicology : official journal of the American College of Medical Toxicology
          Springer Nature
          1937-6995
          1556-9039
          September 2016
          : 12
          : 3
          Affiliations
          [1 ] Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York, NY, USA. larissala@gmail.com.
          [2 ] New York Harbor Veterans Affairs Medical Center and New York University Langone Medical Center Nephrology Section, New York, NY, USA.
          [3 ] Ronald O. Perelman Department of Emergency Medicine, New York University School of Medicine, New York, NY, USA.
          [4 ] College of Pharmacy and Health Sciences, St. John's University, Jamaica, NY, USA.
          [5 ] Perlmutter Cancer Center, New York University, New York, NY, USA.
          Article
          10.1007/s13181-016-0543-y
          10.1007/s13181-016-0543-y
          4996783
          26987988

          Comments

          Comment on this article